Christiane Chéreau
University of Paris
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Christiane Chéreau.
Hepatology | 2004
Alexis Laurent; Carole Nicco; Jeanne Tran Van Nhieu; Didier Borderie; Christiane Chéreau; Filomena Conti; Patrick Jaffray; Olivier Soubrane; Yvon Calmus; Bernard Weill; Frédéric Batteux
Nonalcoholic fatty liver disease, frequently associated with obesity, can lead to nonalcoholic steatohepatitis (NASH) and cirrhosis. The pathophysiology of NASH is poorly understood, and no effective treatment is available. In view of a potential deleterious role for reactive oxygen species (ROS), we investigated the origin of ROS overproduction in NASH. Mitochondrial production of ROS and its alterations in the presence of antioxidant molecules were studied in livers from ob/ob mice that bear a mutation of the leptin gene and develop experimental NASH. N‐acetyl‐cysteine and the superoxide dismutase (SOD) mimics ambroxol, manganese [III] tetrakis (5,10,15,20 benzoic acid) (MnTBAP), and copper [II] diisopropyl salicylate (CuDIPS) were used to target different checkpoints of the oxidative cascade to determine the pathways involved in ROS production. Liver mitochondria from ob/ob mice generated more O2°− than those of lean littermates (P < .01). Ex vivo, all three SOD mimics decreased O2°− generation (P < .001) and totally inhibited lipid peroxidation (P < .001) versus untreated ob/ob mice. Those modifications were associated with in vivo improvements: MnTBAP and CuDIPS reduced weight (P < .02) and limited the extension of histological liver steatosis by 30% and 52%, respectively, versus untreated ob/ob mice. In conclusion, these data demonstrate deleterious effects of superoxide anions in NASH and point at the potential interest of nonpeptidyl mimics of SOD in the treatment of NASH in humans. (HEPATOLOGY 2004;39:1277–1285.)
Transgenic Research | 1999
Frédérique Taboit‐Dameron; Benoit Malassagne; Celine Viglietta; Claudine Puissant; Mathieu Leroux-Coyau; Christiane Chéreau; Joe Attal; Bernard Weill; Louis-Marie Houdebine
Whatever its field of application, animal transgenesis aims at a high level of reproducible and stable transgene expression. In the case of xenotransplantation, prevention of hyperacute rejection of grafts of animal origin requires the use of organs expressing human inhibitors of complement activation such as CD55 (DAF) and CD59. Pigs transgenic for these molecules have been produced, but with low and variable levels of expression. In order to improve cDNA expression, a vector containing the 5′HS4 region from the LCR of the chicken β‐globin locus and the promoter and the first intron from the human EF1α gene, was used to co‐express human CD55 and CD59 cDNAs in transgenic rabbits. The transgenic lines with the 5′HS4 region displayed dramatically enhanced CD55 and CD59 mRNA concentrations in brain, heart, kidney, liver, lung, muscle, spleen and aortic endothelial cells in comparison with the transgenic lines without the 5′HS4 region. In the absence of the 5′HS4 region, only some of the transgenic lines displayed specific mRNAs and at low levels. Human CD55 and CD59 proteins were detectable in mononuclear cells from transgenic rabbits although at a lower level than in human mononuclear cells. On the other hand, primary aortic endothelial cells from a bi‐transgenic line were very efficiently protected in vitro against human complement‐dependent lysis. Transgenic rabbits harbouring the two human inhibitors of complement activation, CD55 and CD59, can therefore be used as new models in xenotransplantation. Moreover, the vector containing the 5′HS4 region from the LCR of the chicken β‐globin locus seems appropriate not only for xenotransplantation but also for any other studies involving transgenic animals in which cDNAs have to be expressed at a high level in all cell types.
Xenotransplantation | 2003
Benoı̂t Malassagne; J. M. Regimbeau; Frédérique Taboit; F. Troalen; Christiane Chéreau; N. Moiré; Joe Attal; F. Batteux; Filomena Conti; Yvon Calmus; Didier Houssin; Louis-Marie Houdebine; Bernard Weill
Abstract:u2002Background: Hyperacute rejection (HAR) of discordant xenografts in the pig‐to‐human combination can be prevented using tranplants expressing transgenic molecules that inhibit human complement. Hypodermin A (HA), a serine esterase that degrades C3, was tested in the guinea‐pig‐to‐rat and in the pig‐to‐human combinations.
European Journal of Clinical Investigation | 2001
P. Podevin; Leonor Correia; Jean-Claude Montet; Filomena Conti; Christiane Chéreau; Yvon Calmus; Raoul Poupon
Background The molecular mechanisms involved in the immunosuppressive properties of bile salts are partly unknown.
European Journal of Immunology | 1998
Nathalie Atia; Luc Camoin; Guillaume Duflos; Benoı̂t Malassagne; Christiane Chéreau; Franco Filipponi; Saı̈d Mahboub; Frédéric Batteux; Filomena Conti; Jean-Claude Michalski; Didier Houssin; Yvon Calmus; Bernard Weill
Preformed antibodies are involved in xenograft rejection. The purpose of this work was to characterize porcine xenoantigens recognized by human preformed IgG (hpIgG), and to investigate the role of hpIgG in xenogeneic rejection. IgG eluted from porcine livers perfused with human plasma, human sera and total human IgG were immunoblotted on porcine aortic endothelial cell extracts. The amino acid sequence of a 76‐kDa antigen constantly revealed was 100u2009% homologous with porcine serotransferrin (psTf). hpIgG from human sera, human IgG1 and IgG2 and F(abu2009′u2009)2u2009γ specifically bound to psTf. Neutralization by psTf abolished that binding. Although α1,u20093‐linked galactose residues (Galα1,3Gal) is the dominant epitope recognized by preformed antibodies in the swine‐to‐human combination, the analysis of carbohydrate composition of psTf showed that the molecule was devoid of Galα1,3Gal moieties and that preformed anti‐psTf IgG bound to epitopes localized on the peptide core of the molecule. Purified human anti‐psTf IgG antibodies were able to bind to psTf linked to its receptor on porcine endothelial cells, and to kill those cells through antibody‐dependent cellular cytotoxicity.
Journal of the National Cancer Institute | 2006
Jérôme Alexandre; Carole Nicco; Christiane Chéreau; Alexis Laurent; Bernard Weill; François Goldwasser; Frédéric Batteux
Biomedicine & Pharmacotherapy | 2005
Carole Nicco; Alexis Laurent; Christiane Chéreau; Bernard Weill; Frédéric Batteux
American Journal of Physiology-heart and Circulatory Physiology | 2003
Jean-Christophe Schneider; Driss El Kebir; Christiane Chéreau; Sophie Lanone; Xiao-Lin Huang; Anthony de Buys Roessingh; Jean-Christophe Mercier; Josette Dall'ava-Santucci; A. Tuan Dinh-Xuan
American Journal of Physiology-heart and Circulatory Physiology | 2002
Jean‐Christophe Schneider; Driss El Kebir; Christiane Chéreau; Jean-Christophe Mercier; Josette Dall'ava-Santucci; A. Tuan Dinh-Xuan
Experimental Cell Research | 1998
Benoı̂t Malassagne; Frédérique Taboit; Filomena Conti; Frédéric Batteux; Nathalie Atia; Christiane Chéreau; Hélène Conjeaud; Marie-Claire Théron; Joe Attal; Filip Braet; Louis-Marie Houdebine; Yvon Calmus; Didier Houssin; Bernard Weill